Skip to main content

Table 1 Clinical features of DLBCL patients at the time of diagnosis (n = 74)

From: Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma

  All group
(n = 74)
TP53mut
(n = 12)
TP53wt
(n = 62)
P-value
(TP53mut vs. TP53wt)
Mean age (yrs) 52.8 ± 14.3 50.3 ± 10.6 58.6 ± 18.5 0.347
Sex     0.403
 M 35 7 28  
 F 39 5 34  
B-symptoms     0.016
 No 36 2 34  
 Yes 38 10 28  
Performance score     0.352
 0 + 1 57 8 49  
 2–3 17 4 13  
Stage     0.264
 I-II 7 0 7  
 III-IV 67 12 55  
Extranodal foci     0.074
 No 42 4 38  
 Yes 32 8 24  
Splenomegaly     0.044
 No 59 7 52  
 Yes 15 5 10  
Bone marrow involvement     0.028
 No 51 4 47  
 Yes 23 8 15  
S-LDH     0.296
 Normal 41 5 36  
 Elevated 33 7 26  
IPI score     0.018
 0–2 21 0 21  
 3–5 53 12 41  
Therapy response
 CR 58 7 51 0.066
  1. Abbreviations: M male, F female, S-LDH serum lactate dehydrogenase, IPI International Prognostic Index, CR complete remission